Progress on new vaccine strategies against chronic viral infections

Journal of Clinical Investigation

Volumn 114, Issue 4, 2004, Pages 450-462

  Berzofsky, Jay A ^a   Ahlers, Jeffrey D ^b   Janik, John ^a   Morris, John ^a   Oh, SangKon ^a   Terabe, Masaki ^a   Belyakov, Igor M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; PEPTIDE DERIVATIVE; RECOMBINANT DNA; HEPATITIS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT OUTCOME; VACCINATION; VERRUCA VULGARIS; VIRUS INFECTION; WART VIRUS; BIOLOGICAL MODEL; CELLULAR IMMUNITY; CHRONIC DISEASE; CLINICAL TRIAL; IMMUNOLOGY; PAPILLOMA VIRUS;

AIDS VACCINES; CHRONIC DISEASE; CLINICAL TRIALS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MODELS, BIOLOGICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIRAL HEPATITIS VACCINES; VIRAL VACCINES;

EID: 4344686181     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422674     Document Type: Review

References (149)

1. Belshe, R.B. 2004. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 103:177-185.
2. Hilleman, M.R. 2001. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine. 19:1837-1848.
3. McAleer, W.J., et al. 1984. Human hepatitis B vaccine from recombinant yeast. Nature. 307:178-180.
4. + T cell responses associated with control of viremia. Science. 278:1447-1450,
5. +) T-cell response in acute hepatitis C. Gastroenterology. 117:933-941.
6. Thimme, R., et al. 2001. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194:1395-1406.
7. Grakoui, A., et al. 2003. HCV persistence and immune evasion in the absence of memory T cell help. Science. 302:659-662.
8. + T cells. Nature. 417:95-98.
9. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708-712.
10. Masopust, D., Vezys, V., Marzo, A.L., and Lefrancois, L. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 291:2413-2417.
11. + effector and memory T cell generation. Nat. Immunol. 4:835-842.
12. Wherry, E.J., et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225-234.
13. Missale, G., et al. 1996. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98:706-714.
14. Diepolder, H.M., et al. 1995. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 346:1006-1007.
15. Gerlach, J.T., et al. 2003. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 125:80-88.
16. Mascola, J.R., et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
17. Baba, T.W., et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
18. Rowland-Jones, S., Tan, R., and McMichael, A. 1997. Role of cellular immunity in protection against HIV infection. Adv. Immunol. 65:277-346.
19. Goulder, P.J.R., Rowland-Jones, S.L., McMichael, A.J., and Walker, B.D. 1999. Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS. 13(Suppl A):S121-S136.
20. Levy, J.A. 1993. Pathogenesis of human immunodeficiency virus infection [review]. Microbiol. Rev. 57:183-289.
21. Letvin, N.L. 2002. Strategies for an HIV vaccine. J. Clin. Invest. 110:15-20. doi:10.1172/JCI200215985.
22. + cell depletion or CMV infection. Clin. Immunol. Immunopathol. 65:227-233.
23. + lymphocytes. Science. 283:857-860.
24. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
25. Barouch, D.H., et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:486-492.
26. Hanke, T., et al. 1998. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine. 16:439-445.
27. Otten, G., et al. 2003. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J. Virol. 77:6087-6092.
28. Amara, R.R., et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:69-74.
29. Shiver, J.W., et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:331-335.
30. Casimiro, D.R., et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305-6313.
31. Barouch, D.H., et al. 2002. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:335-339.
32. Berzofsky, J.A., Ahlers, J.D., and Belyakov, I.M. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1:209-219.
33. Belyakov, I.M., et al. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. U. S. A. 95:1709-1714.
34. + cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102:2072-2081.
35. Belyakov, I.M., Hammond, S.A., Ahlers, J.D., Glenn, G.M., and Berzofsky, J.A. 2004. Transcutaneous immunization induces mucosal CTL and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113:998-1007. doi:10.1172/JCI200420261.
36. Belyakov, I.M., et al. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7:1320-1326.
37. Murphey-Corb, M., et al. 1999. Selective induction of protective MHC class I restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J. Immunol. 162:540-549.
38. Belyakov, I.M., and Berzofsky, J.A. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity. 20:247-253.
39. Kim, J.J., Yang, J.S., Dentchev, T., Dang, K., and Weiner, D.B. 2000. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J. Interferon Cytokine Res. 20:487-498.
40. Ahlers, J.D., et al. 2002. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc. Natl. Acad. Sci. U. S. A. 99:13020-13025.
41. + T-cell approach feasible? [review]. Nat. Rev. Immunol. 2:283-291.
42. Wyatt, R., et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393:705-711.
43. Gorny, M.K., et al. 2002. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76:9035-9045.
44. Sharon, M., et al. 2003. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (Camb.). 11:225-236.
45. Ferrari, G., et al. 1997. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. U. S. A. 94:1396-1401.
46. Shiver, J. 2003. A non-replicating adenoviral vector as a potential HIV vaccine. Res. Initiat. Treat. Action. 8:14-16.
47. Pinto, L.A., et al. 1999. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS. 13:2003-2012.
48. Bartlett, J.A., et al. 1998. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. AIDS. 12:1291-1300.
49. Beddows, S., Lister, S., Cheingsong, R., Bruck, C., and Weber, J. 1999. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73:1740-1745.
50. Schooley, R.T., et al. 2000. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1- infected individuals across aspectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J. Infect. Dis. 182:1357-1364.
51. Lambert, J.S., et al. 2001. A phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine. 19:3033-3042.
52. Kahn, J.O., Cherng, D.W., Mayer, K., Murray, H., and Lagakos, S. 2000. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA. 284:2193-2202.
53. Moss, R.B., et al. 2000. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. J. Acquir. Immune Defic. Syndr. 24:264-269.
54. Robbins, G.K., et al. 2003. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 17:1121-1126.
55. + cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 180:290-298.
56. Clements-Mann, M.L, et al. 1998. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. Infect. Dis. 177:1230-1246.
57. Gupta, K., et al. 2002. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J. Acquir. Immune Defic. Syndr. 29:254-261.
58. Belshe, R.B., et al. 2001. Safety and immunogenidcy of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 183:1343-1352.
59. Gorse, GJ., Patel, G.B., and Belshe, R.B. 2001. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers. AIDS Res. Hum. Retroviruses. 17:1175-1189.
60. Cao, H., et al. 2003. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 187:887-895.
61. McConkey, S.J., et al. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9:729-735.
62. Novitsky, V., et al. 2002. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J. Virol. 76:10155-10168.
63. Mwau, M., and McMichael, A.J. 2003. A review of vaccines for HIV prevention. J. Gene Med. 5:3-10.
64. Jobes, D.V., et al. 2003. Molecular phylogenetic and epidemiologic study of HIV-1 infected individuals from a large-scale phase III vaccine efficacy trial (VAX004). Presented at: AIDS Vaccine 2003 Conference. September 18-21. New York, New York, USA.
65. Richman, D.D., Wrin, T., Little, S.J., and Petropoulos, C.J. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
66. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature. 422:307-312.
67. Montefiori, D.C., et al. 2003. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J. Immunol. 170:3906-3914.
68. Burton, D.R., et al. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
69. Gray, R.H., et al. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 357:1149-1153.
70. Quinn, T.C., et al. 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1, Rakai Project Study Group. N. Engl. J. Med. 342:921-929.
71. Duseja, A., et al. 2002. Hepatitis B and C virus - prevalence and prevention in health care workers. Trop. Gastroenterol. 23:125-126.
72. Koff, R.S. 2003. Hepatitis vaccines: recent advances. Int. J. Parasitol. 33:517-523.
73. Weiner, A.J., et al. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. U. S. A. 89:3468-3472.
74. Takaki, A., et al. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6:578-582.
75. Racanelli, V., and Rehermann, B. 2003. Hepatitis C virus infection: when silence is deception. Trends Immunol. 24:456-464.
76. Isaguliants, M.G., and Ozeretskovskaya, N.N. 2003. Host background factors contributing to hepatitis C virus clearance. Curr. Pharm. Biotechnol. 4:185-193.
77. Choo, Q.L., et al. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 91:1294-1298.
78. Esumi, M., et al. 1999. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch. Virol. 144:973-980.
79. Tan, S.L., Pause, A., Shi, Y., and Sonenberg, N. 2002. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discov. 1:867-881.
80. Lai, M.E., et al. 1994. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet. 343:388-390.
81. Major, M.E., et al. 2002. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76:6586-6595.
82. Mehta, S.H., et al. 2002. Protection against persistence of hepatitis C. Lancet. 359:1478-1483.
83. + memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J. Virol. 77:4781-4793.
84. + T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197:1645-1655.
85. Shirai, M., et al. 1995. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154:2733-2742.
86. Cerny, A., et al. 1995. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J. Clin. Invest. 95:521-530.
87. Battegay, M., et al. 1995. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J. Virol. 69:2462-2470.
88. Sarobe, P., et al. 1998. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 102:1239-1248.
89. Saito, T., et al. 1997. Plasmid DNA-based immunization for hepatitis C virus structural proteins, immune responses in mice. Gastroenterology. 112:1321-1330.
90. Frelin, L., et al. 2003. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther. 10:686-699.
91. Pancholi, P., Perkus, M., Tricoche, N., Liu, Q., and Prince, A.M. 2003. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J. Virol. 77:382-390.
92. Makimura, M., et al. 1996. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine. 14:28-36.
93. Matsui, M., Moriya, O., and Akatsuka, T. 2003. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine. 21:1629-1639.
94. Lechmann, M., et al. 2001. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology. 34:417-423.
95. Qiao, M., Murata, K., Davis, A.R., Jeong, S.-H., and Liang, T.J. 2003. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology. 37:52-59.
96. Walboomers, J.M., et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
97. Harro, C.D., et al. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer. Inst. 93:284-292.
98. Schiller, J.T., and Lowy, D.R. 2001. Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin. Biol. Ther. 1:571-581.
99. Kirnbauer, R., et al. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929-6936.
100. Greenstone, H.L., et al. 1998. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. U. S. A. 95:1800-1805.
101. Pinto, L.A., et al. 2003. Cellular immune responses to HPV-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188:327-338.
102. Koutsky, L.A., et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
103. Munger, K., Phelps, W.C., Bubb, V., Howley, P.M., and Schlegel, R. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417-4421.
104. Borysiewicz, L.K., et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1523-1527.
105. van Driel, W.J., et al. 1999. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur. J. Cancer. 35:946-952.
106. Muderspach, L., et al. 2000. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res. 6:3406-3416.
107. Lacey, CJ., et al. 1999. Phase IIa safety and immunogenicity of a therapeutic vaccine, TAGW, in persons with genital warts. J. Infect. Dis. 179:612-618.
108. Klencke, B., et al. 2002. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin. Cancer Res. 8:1028-1037.
109. Sheets, E.E., et al. 2003. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol. 188:916-926.
110. +) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol. 73:5402-5410.
111. Santin, A.D., Bellone, S., Gokden, M., Cannon, M.J., and Parham, G.P. 2002. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N. Engl. J. Med. 346:1752-1753.
112. Goldstone, S.E., Palefsky, J.M., Winnett, M.T., and Neefe, J.R. 2002. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis. Colon Rectum. 45:502-507.
113. Berzofsky, J.A., et al. 1999. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. Immunol. Rev. 170:151-172.
114. Boehncke, W.-H., et al. 1993. The importance of dominant negative effects of amino acids side chain substitution in peptide-MHC molecule interactions and T cell recognition. J. Immunol. 150:331-341.
115. Ahlers, J.D., Takeshita, T., Pendleton, C.D., and Berzofsky, J.A. 1997. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. U. S. A. 94:10856-10861.
116. Ahlers, J.D., Belyakov, I.M., Thomas, E.K., and Berzofsky, J.A. 2001. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J. Clin. Invest. 108:1677-1685. doi:10.1172/JCI200113463.
117. Pogue, R.R., Eron, J., Frelinger, J.A., and Matsui, M. 1995. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. U. S. A. 92:8166-8170.
118. Tourdot, S., et al. 2000. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1- associated peptides: implication in the identification of cryptic tumor epitopes. Eur. J. Immunol. 30:3411-3421.
119. Okazaki, T., Pendleton, D.C., Lemonnier, F., and Berzofsky, J.A. 2003. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J. Immunol. 171:2548-2555.
120. Ahlers, J.D., Belyakov, I.M., and Berzofsky, J.A. 2003. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr. Mol. Med. 3:285-301.
121. Ahlers, J.D., Dunlop, N., Alling, D.W., Nara, P.L., and Berzofsky, J.A. 1997. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNFα synergize with IL-12 to enhance induction of CTL. J. Immunol. 158:3947-3958.
122. Ahlers, J.D., Belyakov, I.M., Matsui, S., and Berzofsky, J.A. 2001. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13:897-908.
123. Belyakov, I.M., Ahlers, J.D., Clements, J.D., Strober, W., and Berzofsky, J.A. 2000. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. J. Immunol. 165:6454-6462.
124. Iwasaki, A., Stiernholm, B.J.N., Chan, A.K., Berinstein, N.L., and Barber, B.H. 1997. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158:4591-4601.
125. Oh, S., Berzofsky, J.A., Burke, D.S., Waldmann, T.A., and Perera, L.P. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. U. S. A. 100:3392-3397.
126. Hodge, J.W., et al. 1999. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59:5800-5807.
127. Biragyn, A., et al. 2002. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood. 100:1153-1159.
128. Biragyn, A., Tani, K., Grimm, M.C., Weeks, S., and Kwak, L.W. 1999. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17:253-258.
129. Klinman, D.M., Barnhart, K.M., and Conover, J. 1999. CpG motifs as immune adjuvants. Vaccine. 17:19-25.
130. Horner, A.A., et al. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167:1584-1591.
131. Terabe, M., and Berzofsky, J.A. 2004. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16:157-162.
132. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-5218.
133. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160:1212-1218.
134. + regulatory T cells in antitumor therapy reveals alternative cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
135. Kronenberg, M., and Gapin, L. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2:557-568.
136. Terabe, M., et al. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-520.
137. Terabe, M., Park, J.M., and Berzofsky, J.A. 2003. Role of IL-13 in negative regulation of anti-tumor immunity. Cancer Immunol. Immunother. 53:79-85.
138. Terabe, M., et al. 2003, Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance; abrogation prevents tumor recurrence. J. Exp. Med. 198:1741-1752.
139. Egen, J.G., Kuhns, M.S., and Allison, J.P. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3:611-618.
140. Walunas, T.L., et al. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:405-413.
141. Alexander-Miller, M.A., Leggatt, G.R., and Berzofsky, J.A. 1996. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 93:4102-4107.
142. Derby, M.A., Alexander-Miller, M.A., Tse, R., and Berzofsky, J.A. 2001. High avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low avidity CTL. J. Immunol. 166:1690-1697.
143. Gallimore, A., Dumrese, T., Hengartner, H., Zinkernagel, R.M., and Rammensee, H.G. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1647-1657.
144. Snyder, J.T., Alexander-Miller, M.A., Berzofsky, J.A., and Belyakov, I.M. 2003. Molecular mechanisms and biological significance of CTL avidity. Curr. HIV Res. 1:287-294.
145. Oh, S., et al. 2003. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J. Immunol. 170:2523-2530.
146. Belyakov, I.M., Moss, B., Strober, W., and Berzofsky, J.A. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. U. S. A. 96:4512-4517.
147. Yang, Z.Y., et al. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77:799-803.
148. Hel, Z., et al. 2000. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. 6:1140-1146.
149. Berzofsky, J.A., et al. 2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer [review]. J. Clin. Invest. 113:1515-1525. doi:10.1172/JCI200421926.